Nov 6 (Reuters) - Emergent BioSolutions Inc EBS.N:
EMERGENT BIOSOLUTIONS SUPPORTS NEW CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF BRINCIDOFOVIR IN TREATING MPOX VIRUS ACROSS AFRICA
EMERGENT BIOSOLUTIONS INC - STUDY TO EVALUATE SAFETY AND EFFICACY OF TEMBEXA FOR MPOX
EMERGENT BIOSOLUTIONS INC - MOSA TRIAL TO BEGIN IN DRC AND NEIGHBORING COUNTRIES
Source text: ID:nGNX83kM6m
Further company coverage: EBS.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.